JB Chemicals and Pharmaceuticals, a Rs.1,200 crore plus pharma major, has maintained its top line and bottom line at almost same level during the second quarter ended September 2016 due to lower exports. Its net profit increased by single digit of 7.2 per cent to Rs.45.20 crore from Rs.42.15 crore in the corresponding period of last year. Its net sales increased only by 2.9 per cent to Rs.293.12 crore from Rs.284.94 crore. EPS improved slightly to Rs.5.32 from Rs.4.97 in the last period.

Its domestic formulations business improved by 12.1 per cent to Rs.125.84 crore. The company has lined up several new product launches in near future. The contrast media products sales in domestic market at Rs.11.11 crore registered growth of 2.3 per cent. The formulations exports declined by 1.3 per cent to Rs.131.35 crore. Its exports to Rest of the World markets, however, improved by 13.3 per cent to Rs.100.43 crore. Exports to Russia-CIS impacted due to poor demand conditions on account of currency issues.

US FDA has approved ANDA for oxybutynin chloride extended release tablets USP, 5 mg, 10 mg and 15 mg. The company expects to commence commercial supplies in the current quarter. Its APIs sales declined by 7.1 per cent to Rs.20.67 crore.

For the first half ended September 2016, JB Chemicals' consolidated net sales increased by 5.4 per cent to Rs.598.97 crore from Rs.568.53 crore in the similar half of last year. Its net profit moved up by 16.2 per cent to Rs.95.05 crore from Rs.81.79 crore.